The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.


Higher doses of the blood-thinner Plavix were no better at preventing sentiment attacks, blood clots or undoing than the pillar disgrace prescribe in patients who had received artery-opening stents, immature on shows. The higher portion - twice the usual amount - was tested in patients with "high platelet reactivity," sense they failed to come back to the drug at lower doses nolvadex. Plavix (clopidogrel) helps intercept clots from forming in patients who have squat platelet reactivity and who have had stents inserted to stand open blocked arteries.



But the rejuvenated study "doesn't support" physicians using the higher, 150-milligram dosage of Plavix after stenting, according to analyse lead author Dr Matthew Price, who presented the findings Tuesday at the annual gathering of the American Heart Association in Chicago. So, the deliberate over leaves an vital question unanswered: How to manage heart patients who don't retort well to Plavix? "It remains unresolved to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn buy isobutyl nitrate. "It's an powerful cram to have done but the humour issues are that a significant proportion of the patients remained with intoxication platelet reactivity even after being on the higher dose".



Previous, smaller studies had indicated that Plavix might have more of an implication if the administer was doubled. "Platelet reactivity varies widely," illustrious Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a capital reactivity storey is associated with poorer outcomes after angioplasty and/or stenting. But until now, a sharp get ahead in the amount of Plavix "has not been tested in a rotund randomized clinical trial," he said.